ANGLE, based at Surrey Research Park, has completed two major cancer testing projects with AstraZeneca, helping to improve how treatments are matched to patients. Their blood-based technology offers a less invasive way to track how cancers respond to treatment in real time.
Now validated and in use by AstraZeneca, these tests will also support wider clinical trials and personalised medicine. ANGLE is a key member of Surrey Research Park’s CancerBusters campaign, which brings together industry, academics and healthcare providers to exchange knowledge, and drive tangible progress in cancer diagnostics, treatment and care.
Read more here